MAIA Biotechnology, Inc.

NYSE American MAIA

MAIA Biotechnology, Inc. Operating Income for the Trailing 12 Months (TTM) ending September 30, 2024: USD -18.38 M

MAIA Biotechnology, Inc. Operating Income is USD -18.38 M for the Trailing 12 Months (TTM) ending September 30, 2024, a 3.78% change year over year. Operating income is the profit earned by a company from its normal business operations before interest and taxes are deducted.

MAIA Biotechnology, Inc. Operating Income for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -19.10 M, a -37.59% change year over year.
MAIA Biotechnology, Inc. Operating Income for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -13.88 M, a -70.71% change year over year.
MAIA Biotechnology, Inc. Operating Income for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -8.13 M.

Key data

Date	Operating Income	EBIT	EBITDA	Net Income

NYSE American: MAIA

MAIA Biotechnology, Inc.

CEO	Dr. Vlad Vitoc M.B.A., M.D.
IPO Date	July 28, 2022
Location	United States
Headquarters	444 West Lake Street
Employees	13
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded in 2018 and is headquartered in Chicago, Illinois.

Key trends

Past 5 years